Histological grade in invasive ductal carcinoma of breast correlates with the proliferafive activity evaluated by BrdU: An immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status

Pathology International

Volumn 46, Issue 6, 1996, Pages 417-425

  Moriki, Toshiaki ^a,b   Takahashi, Tamotsu ^a   Hiroi, Makoto ^b   Yamane, Toshiko ^c   Hara, Hiroshi ^d  

^a Dept of Clin Laboratory Medicine ^*  (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c The Public Health Institute of Kochi Prefecture   (Japan)

^d Aichi Institute of Technology   (Japan)

Author keywords

BrdU; breast carcinoma; c erbB 2; estrogen receptor; histological grade; Nottingham method

Indexed keywords

ESTROGEN RECEPTOR; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 0029829229     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1996.tb03632.x     Document Type: Article

References (39)

1. Japanese Breast Cancer Society. The general rules for clinical and pathological recording of breast cancer. Jpn. J. Surg. 1989; 19:612-632.
2. World Health Organization. Histological Typing of Breast Tumors, 2nd edn. WHO, Geneva, 1981.
3. International Union Against Cancer (Spiessl B, ed.). TNM Atlas: Illustrated Guide to the JNM/pTNM Classification of Malignant Tumours, 3rd edn. Springer-Verlag, Berlin, 1989; 174-183.
4. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br. J. Cancer 1957; 11: 359-377.
5. Doussal VL, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914-1921.
6. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
7. Biesterfeld S, Noll I, Noll E, Wohltmann D, Boecking A. Mitotic frequency as a prognostic factor in breast cancer. Hum. Pathol. 1995; 26: 47-52.
8. Meyer JS, Province M. Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res. Treat. 1988; 12: 191-204.
9. Myer JS, Koehm SL, Hughes JM et al. Bromodeoxyuridine labeling for S-phase measurement in breast carcinoma. Cancer 1993; 71: 3531-3540.
10. Weidner N, Moore DH, Ljung BM et al. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am. J. Surg. Pathol. 1993; 17: 987-994.
11. Siitonen SM, Isola JJ, Rantala IS, Helin HJ. Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. Am. J. Clin. Pathol. 1993; 99: 226-231.
12. Leonardi E, Girlando S, Serio G et al. PCNA and Ki-67 expression in breast carcinoma: Correlations with clinical and biological variables. J. Clin. Pathol. 1992; 45: 416-419.
13. Barnard NJ, Hall PA, Lemoine NR, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J. Pathol. 1987; 152: 287-295.
14. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation and DNA content in breast carcinoma: Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis and mitotic count. Cancer 1990; 65: 1180-1184.
15. Kallioniemi OP, Blanco G, Alavaikko M et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: A proposed classification of DNA histogram in breast cancer. Cancer 1988; 62: 2183-2190.
16. McGuire WL. Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J. Clin. Oncol. 1988; 6: 1071-1072.
17. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node negative breast cancer. N. Engl. J. Med. 1992; 326: 1756-1761.
18. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD. p53 and c-erbB-2 protein expression in breast carcinomas: An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am. J. Clin. Pathol. 1992; 98: 408-418.
19. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl Cancer Inst. 1992; 84: 1109-1114.
20. Haerslev T, Jacobsen GK. An immunohistochemical study of p53 with correlations of histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum. Pathol. 1995; 26: 295-301.
21. Stenkvist B, Bengtsson E, Eriksson O, Jarkans T, Nordin B, Westman-Naeser S. Histopathological systems of breast cancer classification: Reproducibility and clinical significance. J. Clin. Pathol. 1983; 36: 392-398.
22. Fisher ER, Gregorio RM, Fisher B. The pathology of invasive breast cancer: A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 1975; 36: 1-85.
23. Fisher ER, Redmond C, Fisher B. Histological grading of breast cancer. Pathol. Annu. 1980; 15: 239-251.
24. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J. The importance of histological grade in long-term prognosis of breast cancer: A study of 1010 patients, uniformly treated at the Institut Gustave Roussy. J. Clin. Oncol. 1987; 5: 1378-1386.
25. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991; 253: 49-53.
26. Porter PL, Gown AM, Kramps SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. Am. J. Pathol. 1992; 140: 145-153.
27. Venter D, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification. Lancet 1987; 2: 69-72.
28. Berger MS, Locher GW, Saurer S et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988; 48: 1238-1243.
29. Van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 1988; 319: 1239-1245.
30. Walker RA, Gullick WJ, Varley JM. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br. J. Cancer 1989; 60: 426-429.
31. Wright C, Angus B, Nicholson S et al. Expression of C-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res. 1989; 49: 2087-2090.
32. Tsuda H, Hirohashi S, Snimosato Y et al. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: Its correlation with gene amplification and long-term survival patients. Jpn. J. Cancer Res. 1990; 81: 327-332.
33. Winstanley J, Cooke T, Murry GD. The long-term prognostic significance of c-erbB-2 in primary breast cancer. Br. J. Cancer 1991; 63: 447-450.
34. De Potter CR, Schelfhout AM, Verbeeck P et al. Neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. Hum. Pathol. 1995; 26: 601-606.
35. Cardiff RD. Cellular and molecular aspects of neoplastic progression in the mammary gland. Eur. J. Cancer Clin. Oncol. 1988; 24: 15-20.
36. Poller DN, Roberts EC, Bell JA, Elston CW, Blarney RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum. Pathol. 1993; 24: 463-468.
37. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum. Pathol. 1993; 24: 469-476.
38. Kay EW, Walsh CJB, Cassidy M, Curran B, Leader M. c-erbB-2 immunostaining: Problems with interpretation. J. Clin. Pathol. 1994; 47: 816-822.
39. Todd JH, Dowle C, Williams MR et al. A prognostic index in primary breast cancer. Br. J. Cancer 1987; 56: 489-492.